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Abstract 
Background: Anthracycline cardiotoxicity (AC) may manifest years after treatment 
(long-term cardiotoxicity). There is little data on the incidence and natural history of AC 
in the current context, with protocols including lower anthracycline doses. The present 
study prospectively evaluated the incidence, time of occurrence and clinical correlates 
of long-term cardiotoxicity and the evolution of systolic function in patients with breast 
cancer treated with anthracyclines. 
Methods: This study prospectively included 85 consecutive patients undergoing 
chemotherapy (CHT) with anthracyclines without trastuzumab. All patients underwent 
evaluation at baseline, at the end of CHT, 3 months after the end of CHT and 1 and 4 
years subsequent to the beginning of CHT. Clinical data and echocardiographic 
parameters were evaluated in all examinations.  
Results: The mean dose of doxorubicin used was 243.53 mg/m2. Median follow-up of 
the current cohort was 4.5 years. At 1 year the incidence of AC was 1% and at the end 
of the follow-up 16.5% (14 of 85 patients). Therefore, the incidence of long-term 
cardiotoxicity was 15%. Of these 14 patients with AC, 12 had asymptomatic systolic 
dysfunction, 1 had heart failure and 1 suffered sudden death. Fifteen percent developed 
systolic dysfunction during follow–up. An early decline in strain was observed in 
patients who developed long-term AC.  
Conclusions: The incidence of long-term cardiotoxicity in patients treated with low-
cumulative dose of anthracyclines is high, 16.5% at 4.5 years. This was observed in 
almost all cases after the first year of follow-up. Therefore, long-term monitoring may 
be advisable. 
Key words: cardiotoxicity, anthracyclines, cardiomyopathies, drug therapy, heart 
failure, sistolic dysfunction 
 
 
INTRODUCTION 
Anthracyclines are highly effective chemotherapy (CHT) agents of a broad 
spectrum widely used in cancer processes for diseases such as breast cancer, leukemias 
and lymphomas. However, the utility of anthracyclines is limited by cumulative, dose-
related, progressive myocardial damage that may lead to congestive heart failure [1–3]. 
Anthracycline cardiotoxicity (AC), which may manifest years after treatment (long-term 
cardiotoxicity) [4, 5].  
There are discordant data regarding the incidence of AC. Most of the available 
data come from retrospective studies, with substantial variability in the incidence of 
AC, depending on the definition of cardiotoxicity, the cumulative dose of 
anthracyclines, the age of the patients and the drugs used. AC reported ranges from 5%, 
when a cumulative lifetime dose of 400 mg/m2 is reached, up to 48% at 700 mg/m2 [6–
8], when higher doses lead to an exponential increase in risk. In addition, it was found 
that increasing age was associated with an increasing risk of AC [9, 10]. These 
incidences reported of AC may not be an accurate reflection of the true incidence 
nowadays, where regimens are including lower anthracycline doses and an initial 
cardiological evaluation is attempted to exclude patients with underlying heart disease. 
Early detection and prompt therapy of cardiotoxicity appear crucial for substantial 
recovery of cardiac function [11]. 
The aim of the study was to evaluate the incidence of long-term cardiotoxicity 
and the evolution of systolic function during the follow-up, in patients with breast 
cancer treated with anthracyclines without trastuzumab in the current context, excluding 
patients with previous heart disease.  
 METHODS 
Study population 
This prospective and analytical cohort study was conducted in the area of 
Hospital of Fuenlabrada, Madrid.  All consecutive patients were considered  who had 
breast cancer treated with anthracycline-based CHT (adjuvant and neoadjuvant therapy) 
during the period from April 2008 to May 2010, whose age was  between 18 and 80 
years.  
Patients treated with anthracycline therapy followed by trastuzumab were 
excluded.  
Patients were also excluded if they had had a previous cardiac disease (ischemic 
heart disease, moderate or severe valvular heart disease, dilated, restrictive or 
hypertrophic cardiomyopathy), history of heart failure or left ventricular ejection 
fraction (LVEF) < 55%; patients with a poor echocardiographic window, permanent 
atrial fibrillation, renal insufficiency with creatinine > 2 mg/dL or clearance < 30 mL/h, 
previous treatment with anthracyclines or a life expectancy of ≤ 1 year were also 
excluded. 
The local Ethical Committee approved the study, and all patients provided 
written informed consent. 
 
Study protocol 
Patients in the study received one of two different CHT regimens: FECX6 
(Group 1): 5-fluoruracil 600 mg/m2, epirubicin 75 mg/m2 and cyclophosphamide 600 
mg/m2, 1 cycle every 21 days until 6 cycles were completed; ACX4-T (Group 2): 
doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, 1 cycle every 21 days to 
complete 4 cycles followed by paclitaxel (taxol) 80 mg/m2, 1 weekly cycle for 12 
weeks.  
Patients were evaluated on five separate visits: 
— before the start of anthracycline therapy (visit 0); 
— just prior to the last dose of anthracycline CHT (visit 1); 
— 3 months after the last dose of anthracycline CHT (visit 2); 
— 9 months after the last dose of anthracycline CHT (visit 3); 
— 4 years after the start of the CHT (visit 4). 
In the group of patients who received an epirubicin  dose, estimated by using a 
conversion factor of 0.55 (50 mg of doxorubicin = 90 mg of epirubicin), according to 
the recommendations of the Oncology Department and published data [24]. 
Follow-up visits were adapted to previous knowledge of chronic anthracycline 
cardiomyopathy [7, 11, 13, 22]. These time points were adapted to planned oncological 
controls, for ethical concerns and to humanize the research. 
On each visit clinical status, physical examination, as well as signs and 
symptoms of heart failure were evaluated. An electrocardiogram and a complete 
echocardiogram were performed, including measurement of LVEF (BIPLANE method) 
[21] and global longitudinal strain (GLS). Echocardiograms were performed utilizing 
GE Vivid Cardiac Ultrasound (General Electric, Milwaukee, USA), then digitized and 
analyzed using EchoPAC software (GE medical systems, Milwaukee, USA).  
 
Study endpoints 
 The aim of the study was to evaluate the incidence of long-term cardiotoxicity 
in patients with breast cancer treated with anthracyclines. According to the definition of 
cardiotoxicity accepted at the time when the study began [25], AC was defined as new-
onset heart failure, according to the Framingham criteria, reduction in LVEF ≥ 10 
percentage points from baseline with a final LVEF less than 55%, sustained ventricular 
arrhythmias, or sudden cardiac death. 
 Cardiotoxicity was classified in different types depending on the time of 
appearance: acute cardiotoxicity, immediately after the CHT dose; chronic 
cardiotoxicity, within the first year after the start of CHT; and late cardiotoxicity which 
occurs later than a year after CHT has been completed [26–29]. Long-term 
cardiotoxicity includes chronic cardiotoxicity and late cardiotoxicity.  
 The secondary endpoints were to assess the evolution of the left systolic 
function in these patients, in order to establish their role in the early diagnosis of 
cardiotoxicity. 
 
Statistical analyses 
Statistical analyses were performed using the Statistical Package for Social 
Sciences (SPSS), version 15.0 for Windows. Data are summarized as mean with 
standard deviation, or proportions, as in the case of discrete variables. The Paired 
Student t-test was used for comparisons of continuous variables between follow-up and 
baseline visits. Univariate comparisons of patient groups who developed anthracycline 
cardiotoxicity (AC +) or those who did not (AC–), were analyzed by means of the 
Student’s t-test or the Fisher exact test.  
 
RESULTS 
Eighty-five patients (98% women, mean age: 50.4 years) were included in the 
study. The mean dose of doxorubicin used was 243.53 mg/m2 of body surface area. The 
mean follow-up of the present cohort was 52 months (52 ± 8.2 months). Baseline 
characteristics of the patients are shown in Table 1. Ninety percent of the population 
received radiotherapy but only 42% (36 patients) received radiotherapy on the left 
hemithorax or mediastinum. Mean radiotherapy total dose was 5916.13 Gy. Regarding 
heart dose, heart volume that received 30 Gy of radiotherapy (V30 Gy) was 6.3%. 
 At 1 year of follow-up, 2 patients died, one due to sudden cardiac death 
(attributed to cardiotoxicity) and the other due to progression of the oncological disease. 
At the end of follow-up, 8 of the 85 patients had died (9.4%). Seventy-five patients 
attended all scheduled visits. Visit 3 was attended by 99% of patients alive at that time 
and last visit was attended by 100% of patients alive at that time. 
During the first year of follow-up, 1 patient developed AC (1%). After the first 
year, another 13 patients developed cardiotoxicity (late cardiotoxicity). Therefore, at the 
end of the follow-up, 14 patients had developed AC (16.5%) (long-term cardiotoxicity), 
of which: 1 patient had heart failure and left ventricular systolic dysfunction, 12 patients 
had asymptomatic left ventricular systolic dysfunction and 1 patient suffered sudden 
cardiac death. 
 The distribution according to the CHT schemes was: 6 patients from the 
FECx6 group (20% of them) and 8 patients from the ACx4-T group (15%). Regarding 
the clinical variables, the univariate analysis showed no differences in age (50.1 vs. 51.6 
years), body mass index or any of the cardiovascular risk factors between the AC+ and 
AC– groups, as shown in Table 2. There were no significant differences in other clinical 
variables evaluated as radiotherapy, anthracycline dose or CHT scheme. Neither 
differences were found in the proportion of patients who were being treated with 
angiotensin-converting enzyme inhibitors or statins between the groups at the beginning 
of the study. The use of beta-blockers was greater among AC+ patients, although only 2 
patients were being treated with beta-blockers, hence, it was difficult to draw 
conclusions on this point. The main variables in the group of patients who developed 
anthracycline cardiotoxicity (AC +) and those in the group that did not develop 
anthracycline cardiotoxicity (AC–) are summarized in Table 2.  
 
Echocardiographic findings 
All patients had a normal basal systolic function, according to the inclusion 
criteria and selection of candidates for treatment with anthracyclines, with a mean 
LVEF of 67.13 ± 5.9% (Table 3) and there were no differences between different CHT 
protocols. Similarly, all patients presented baseline values of normal global longitudinal 
strain (GLS), with a mean GLS of –18.91 ± 2.8% (Table 3), without differences 
between the groups divided according to CHT protocols. 
At follow-up, a significant decrease was found in LVEF with respect to the 
baseline visit. At visit 3 (9 months after the last dose of anthracyclines and 
approximately 1 year after the baseline visit) the mean LVEF by the Simpson method 
was 64.05 ± 5.3%, which represents a decrease of 3.08% with respect to the baseline 
LVEF (Table 3). At this visit, only 1 patient had developed left ventricular systolic 
dysfunction (1%). At the end of follow-up, visit 4 (52 months post-CHT) mean LVEF 
by Simpson method was 60.89 ± 7.0%, with a significant decrease of 6.24% with 
respect to baseline (p < 0.001; Table 3); at this visit, another 13 (15%) patients had 
developed left ventricular systolic dysfunction. Therefore, it can be seen that most of 
them appear late in follow-up, and are categorized as late cardiotoxicity. It is 
remarkable that the decrease in LVEF from visit 3 (9 months after the last dose of CHT) 
to visit 4 (4 years after the beginning), from 64.05% to 60.89%, respectively; it can be 
appreciated how LVEF continues to decrease markedly after the first year (late 
cardiotoxicity). 
Regarding to ventricular diameters, a significant increase in left ventricular 
diastolic diameter was also detected at visits 3 and 4, and in systolic diameter from visit 
1 to visit 3 as well.  
In Figure 1 differences are shown in LVEF means between AC+ and AC– 
group. There were no significant differences between the AC+ and AC– group from 
baseline to visit 3 (9 months after the last dose of anthracycline). Significant differences 
emerge in the last visit, visit 4 (4 years after the start of CHT), showing a mean LVEF 
of 51.77 ± 5.15% in AC+ group and 62.78 ± 5.82% in AC– group (p < 0.001). The 
greatest percentage decrease in LVEF occurs in AC+ group from visit 3 to visit 4 with a 
decline of LVEF from 62.78% to 51.77%, respectively (late cardiotoxicity). 
Regarding GLS values (Table 3),  a discrete progressive decrease was found 
throughout the visits, but without becoming a significant difference. In Table 4  the 
GLS values are shown at each visit in group AC + and in group AC–.  
In Table 4 the GLS values are shown at each visit in group AC+ and in group 
AC–. Analyzing the decrease in GLS from baseline visit, group AC+ shows a decrease 
in GLS from the baseline visit to visit 2 (3 months after the last dose of anthracycline 
CHT) of 2.59 ± 2.8 while the group AC– only shows a decrease of 1.46 ± 3.6 (p = 0.35). 
There are significant differences in the decrease in GLS from the baseline visit to visit 3 
(9 months after the last dose of anthracycline CHT), the group AC+ shows a decrease of 
3.6 ± 3.21 while the group AC–shows only a decrease of 1.41 ± 3.6 (p = 0.04).  
 
DISCUSSION 
Despite the benefits of anthracyclines in the treatment of cancer, cardiotoxicity 
remains a major concern. There are scant data from prospective studies on 
cardiotoxicity in the current context characterized by regimens that include lower 
anthracycline doses and include an initial cardiological evaluation aimed to rule out 
heart disease. The most important results of the present study are that long-term 
cardiotoxicity due to anthracyclines is high, 16.5% at 4.5 years, and its highest 
incidence was late, observed after the first year post-CHT completion in 13 of the 14 
patients who developed cardiotoxicity. Fourteen of the 85 patients developed 
anthracycline cardiotoxicity, but only one had clinical heart failure, one patient suffered 
sudden cardiac death and 12 patients had asymptomatic left ventricular systolic 
dysfunction. The results of the current study are not consistent with previous incidences 
reported in retrospective studies, from 5%, when a cumulative lifetime dose of 400 
mg/m2 is reached, up to 48% at 700 mg/m2 [6–8] (including symptomatic and 
subclinical cardiotoxicity). A prospective study by Cardinale et al. [11] showed an 
incidence of cardiotoxicity of 9% in 5 years, which is lower that observed in the current 
study; a different definition of cardiotoxicity (LVEF decrease > 10 absolute points, and 
< 50%) may explain the differences in the incidence. 
Another important finding was that cardiotoxicity presentation was mostly 
subclinical. Regarding subclinical cardiotoxicity, a systematic review [30] describes a 
wide variation in the incidence of long-term asymptomatic cardiac dysfunction between 
different studies, with incidences ranging from 0% and 57% in the 25 studies included. 
Differences in anthracycline dose between different studies may explain, in part, the 
wide variation in the incidence of subclinical cardiotoxicity. 
Also to be considered, is that data from large clinical trials with trastuzumab in 
the adjuvant treatment [31–35], with patient populations and doses were more similar to 
those of the present study. In these studies, in the treatment arms with anthracyclines 
alone (without associated trastuzumab), the incidence of clinical heart failure ranged 
between 0.06% and 2.03% and that of left ventricular dysfunction between 2.2% up to 
17%, concordant with the present study.  
Global longitudinal strain is regarded as an early sign of cardiotoxicity [10]. In 
the current study, patients who developed AC have a significantly greater decrease in 
GLS from baseline to visit 3 (9 months after the last dose of anthracycline CHT) than 
those who did not.  
Some previous data showed that cardiotoxicity occurring in almost all cases in 
the first year after the end of treatment [11]. The data herein, however, indicate that a 
monitoring limited to the first year would not detect most of the cases of cardiotoxicity. 
Therefore, longer monitoring may be advisable. 
 
Limitations of the study 
Several limitations warrant mention. First of all is an observational study, at a 
single center. The echocardiograms were analyzed by a cardiology expert in 
echocardiography, off-line and blind to the clinical data of the patients. Intra- and 
interobserver variability was tested with acceptable results and comparable to those of 
other single institution studies, however some degree of bias in these results cannot be 
excluded. A reduction in LVEF was observed in some patients who did not fulfil criteria 
for cardiotoxicity. Although the oncologic diagnosis was the first diagnosis for all 
patients, the study population included patients with early and advanced cancer disease, 
and this fact may have influenced survival and development of late-cardiotoxicity of the 
patients. 
 
CONCLUSIONS 
The incidence of long-term cardiotoxicity in patients treated with a low 
cumulative dose of anthracyclines is high, 16.5% at 4.5 years, observed in almost all 
cases after the first year of follow-up. Therefore, long-term monitoring may be 
advisable. 
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Table 1. Baseline characteristics of the patients. 
Number of patients 85 
Age [years] 50.4 ± 9.03 
Female sex 83 (98%) 
Weight [kg]  69.9 ± 11.7   
High [cm]  1.57 ± 7.1 
Body mass index [kg/m2] 28.41 ± 5.0  
Cardiovascular risk factors: 
Hypertension 
Smoking  
Hyperlipidemia  
Diabetes 
  
26 (31%)  
29 (34%)  
14 (17%)  
10 (12 %) 
Chemotherapy regimen: 
FECx6  
ACx4-T  
  
30 (35%)  
55 (65%)  
Anthracycline dose [mg/m2] 243.53 ± 4.8  
Radiotherapy 36 (42%) 
Beta-blockers treatment 2 (2%) 
ACEI treatment 13 (15%) 
Data are shown as mean standard deviation or number (percentage). FECx6 — 5-fluorouracil, 
epirubicin and cyclophosphamide; ACx4-T — adriamycin (doxorubicin), cyclophosphamide and 
Taxol® (paclitaxel); ACEI — angiotensin-converting enzyme inhibitors 
 
 
 
Table 2. Main clinical variables and echocardiographic parameters in groups AC+ 
and AC–. 
 AC+ AC– P 
Number of patients 14 71  
Age [years] 50.1 ± 9.5 51.6 ± 9.03 0.78 
Body mass index [kg/m2] 28.01 ± 4.6 28.23 ± 4.9 0.87 
Basal LVEF [%] 65.5 ± 5.4 67.4 ± 6.0 0.67 
Hypertension 
Diabetes 
Hyperlipidemia 
Smoking 
35.7 
14.3 
14.3 
42.9 
29.6 
11.3 
16.9 
32.4 
0.75 
0.67 
0.58 
0.74 
Anthracycline dose [mg/m2] 243 ± 4.8 242 ± 4.6 0.73 
Radiotherapy [%] 42.9 42.3 0.97 
Radiotherapy total dose [cGy]  6400.00 5823.08 0.08 
Baseline strain  18.88 ± 2.9 18.91 ± 2.9 0.86 
Beta-blockers treatment [%] 14 0 0.03 
ACEI treatment [%] 7 17 0.68 
Statin treatment [%] 14 13 0.87 
Values are expressed as mean ± standard deviation; values of P calculated by Student's t for the 
differences in means between groups AC+ and AC–.*indicates p-value < 0.05; AC+ — group of 
patients who develop anthracycline cardiotoxicity; AC– — group of patients who do not develop 
cardiotoxicity due to anthracyclines; LVEF — left ventricular ejection fraction; ACEI — angiotensin-
converting enzyme inhibitors 
 
 
 
Table 3. Echocardiographic parameters at the beginning and the follow-up visits. 
 Basal Visit 1 Visit 2 Visit 3  Visit 4 
N (patients) 85 85 84 83 77 
LVEF [%] 67.13 ± 5.9 64.74 ± 
5.6* 
63.26 ± 
5.1* 
64.05 ± 
5.3* 
60.89 ± 
7.0* 
GLS [%] 18.91 ± 2.8 18.32 ± 3.5 17.67 ± 3.7 17.63 ± 3.3 18.1 ± 3.2 
Values expressed as mean ± standard deviation; *indicates p-value < 0.05 compared to baseline values. 
The global longitudinal strain (GLS) is expressed in absolute values; LVEF — left ventricular ejection 
fraction measured by the Simpson method 
 
 
 
Table 4. Global longitudinal strain decreases from baseline value at each visit in the 
AC+ group and AC– group. 
 AC+  AC– P 
N 14 71  
Decrease from baseline to 
visit 1 
2.00 ±3.3 0.98 ± 
2.8 
0.31 
Decrease from baseline to 
visit 2 
2.59 ± 2.8 1.46 ± 
3.6 
0.35 
Decrease from baseline to 
visit 3 
3.6 ± 3.2 1.41 ± 
3.6 
0.04 
Decrease from baseline to 
visit 4 
3.10 ± 2.5 0.76 ± 3.3 0.04 
Values expressed as mean ± standard deviation; AC+ — group of patients who develop anthracycline 
cardiotoxicity; AC– — group of patients who do not develop cardiotoxicity due to anthracyclines. Values 
of P calculated by the Student t-test for the differences in decrease in global longitudinal strain between 
groups of patients who develop cardiac toxicity by anthracyclines (AC+) and those who do not develop 
cardiotoxicity by anthracyclines (AC–) 
 
 
  
 
Figure 1. Left ventricular ejection fraction (LVEF) behaviour in AC+ group and AC– 
group, from baseline to final visit. Values expressed as mean ± standard deviation; AC+ 
— group of patients who develop anthracycline cardiotoxicity; AC– — group of patients 
who do not develop cardiotoxicity due to anthracyclines.  
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